Detalhe da pesquisa
1.
IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies.
Retina
; 43(4): 632-640, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705252
2.
Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
Ophthalmologica
; 245(4): 315-322, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344964
3.
Spinal neurenteric cysts: Associated developmental anomalies and rationale of surgical approaches.
Acta Neurochir (Wien)
; 157(9): 1601-10, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26210479
4.
Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis.
Can J Ophthalmol
; 58(3): 252-261, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863677
5.
Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data.
Am J Ophthalmol
; 236: 12-19, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34695400
6.
Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
Ophthalmol Retina
; 6(5): 377-386, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34968756
7.
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
JAMA Ophthalmol
; 140(1): 20-28, 2022 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34817566
8.
Anti-VEGF Treatment Patterns in Patients With Wet Age-Related Macular Degeneration in Clinical Practice.
Ophthalmic Surg Lasers Imaging Retina
; 52(5): 263-272, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34044715